Nymox Announces US NDA for Fexapotide for BPH
HASBROUCK HEIGHTS, N.J., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that the Company will submit a New Drug Application (NDA) for Fexapotide Triflutate for the treatment of BPH in the US. The Company …